Lubner David Charles

Track

Insider profile

Performance

Overall performance
2.2
Performance over holding periods
2.2
30 days 90 days 120 days
Average return 0% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
1 100% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance
Lubner David Charles's trades of Braveheart Bio, Inc.'s stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Purchase
Price
110.15
Quantity 23,068 +24.9%
Value US$2,875,625
US Arcellx Inc (ACLX)
Transaction date
Proposed sale
Price
201.06
Quantity 17,072
Value US$1,114,873
US Arcellx Inc (ACLX)
Transaction date
Planned sale
Price
460.96
Quantity 60,865 +17.1%
Value US$3,738,035
Transaction date
Purchase
Price
6.85
Quantity 3,600 +inf%
Value US$24,660
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-07 2026-08-07
B Purchase
23,068 +24.9%
110.15
US$2,875,625 		23,068 +24.9% 110.15 US$2,875,625
2026-01-20 2026-01-20
US Arcellx Inc (ACLX)
PrS Proposed sale
17,072
201.06
US$1,114,873 		17,072 201.06 US$1,114,873
2026-01-20 2026-01-20
US Arcellx Inc (ACLX)
PlS Planned sale
60,865 +17.1%
460.96
US$3,738,035 		60,865 +17.1% 460.96 US$3,738,035
2022-11-28 2022-11-23
B Purchase
3,600 +inf%
6.85
US$24,660 		3,600 +inf% 6.85 US$24,660